Literature DB >> 23243111

Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.

Alejandro Ordaz-Farias1, Fania Z Muñoz-Garza, Farah K Sevilla-Gonzalez, Ana Arana-Guajardo, Jorge Ocampo-Candiani, Nancy Treviño-Garza, Ingeborg Becker, Adrian Camacho-Ortiz.   

Abstract

Leishmania sp. is an intracellular parasite that causes a variable degree of clinical manifestations, especially in the skin. We present the case of a 38-year-old male with a chronic history of mucocutaneous disease present since childhood that generated deformity, loss of cartilage in the ears and nose, and scarring that limited his range of motion. The parasite was identified as L. mexicana mexicana. The patient was treated with a 3-month course of oral miltefosine with overwhelming results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243111      PMCID: PMC3541727          DOI: 10.4269/ajtmh.2012.11-0592

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.

Authors:  Wilson Mayrink; Ana Cristina de Carvalho Botelho; Paulo Araújo Magalhães; Sebastião Mariano Batista; Antonio de Oliveira Lima; Odair Genaro; Carlos Alberto da Costa; Maria Norma de Melo; Marilene Susan Marques Michalick; Paul Williams; Magno Dias; Waleska Teixeira Caiaffa; Evaldo do Nascimento; George Luiz Lins Machado-Coelho
Journal:  Rev Soc Bras Med Trop       Date:  2006-02-23       Impact factor: 1.581

2.  Treatment of Bolivian mucosal leishmaniasis with miltefosine.

Authors:  J Soto; J Toledo; L Valda; M Balderrama; I Rea; R Parra; J Ardiles; P Soto; A Gomez; F Molleda; C Fuentelsaz; G Anders; H Sindermann; J Engel; J Berman
Journal:  Clin Infect Dis       Date:  2006-12-27       Impact factor: 9.079

3.  Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.

Authors:  Manuel Calvopina; Eduardo A Gomez; Herbert Sindermann; Philip J Cooper; Yoshihisa Hashiguchi
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

4.  Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.

Authors:  Nishi Shakya; Shraddha A Sane; Preeti Vishwakarma; Preeti Bajpai; Suman Gupta
Journal:  Acta Trop       Date:  2011-06-07       Impact factor: 3.112

5.  Disseminated anergic cutaneous leishmaniasis. An autochthonous case in Texas and the Mexican states of Tamaulipas and Nuevo Leon.

Authors:  M H Simpson; J F Mullins; O J Stone
Journal:  Arch Dermatol       Date:  1968-03

6.  Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.

Authors:  Mansour Nassiri Kashani; Alireza Firooz; Seyed Ebrahim Eskandari; Mohammad Hossein Ghoorchi; Ali Khamesipour; Alireza Khatami; Amir Javadi; Yahya Dowlati
Journal:  Eur J Dermatol       Date:  2007-10-19       Impact factor: 3.328

7.  Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil.

Authors:  Meredith L Turetz; Paulo R Machado; Albert I Ko; Fábio Alves; Achiléa Bittencourt; Roque P Almeida; Niloufar Mobashery; Warren D Johnson; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2002-11-19       Impact factor: 5.226

8.  Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.

Authors:  O Zerpa; M Ulrich; B Blanco; M Polegre; A Avila; N Matos; I Mendoza; F Pratlong; C Ravel; J Convit
Journal:  Br J Dermatol       Date:  2007-04-17       Impact factor: 9.302

Review 9.  CD8 cytotoxic T cells in cutaneous leishmaniasis.

Authors:  J H Ruiz; I Becker
Journal:  Parasite Immunol       Date:  2007-12       Impact factor: 2.280

10.  Cutaneous leishmaniasis in Texas: A northern spread of endemic areas.

Authors:  Natalie A Wright; Lance E Davis; Kent S Aftergut; Charles A Parrish; Clay J Cockerell
Journal:  J Am Acad Dermatol       Date:  2008-02-04       Impact factor: 11.527

View more
  3 in total

Review 1.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

2.  Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.

Authors:  Ayelet Ollech; Michal Solomon; Amir Horev; Shiran Reiss-Huss; Dan Ben-Amitai; Alex Zvulunov; Rivka Friedland; Vered Atar-Snir; Vered Molho-Pessach; Aviv Barzilai; Shoshana Greenberger
Journal:  Acta Derm Venereol       Date:  2020-10-19       Impact factor: 3.875

3.  Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.

Authors:  Saskia van Henten; Annisa Befekadu Tesfaye; Seid Getahun Abdela; Feleke Tilahun; Helina Fikre; Jozefien Buyze; Mekibib Kassa; Lieselotte Cnops; Myrthe Pareyn; Rezika Mohammed; Florian Vogt; Ermias Diro; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.